Zymeworks to Participate in Upcoming Investor Conferences and Events
Zymeworks Inc. (NYSE: ZYME) announced its participation in five upcoming virtual investor conferences. Key events include the Barclays Global Healthcare Conference on March 11, 2021, where Zymeworks will present at 1:15 p.m. ET. Other conferences include the Guggenheim Healthcare Talks and SVB Leerink’s 10th Annual Global Healthcare Conference, both without public presentations. Interested parties can access a live webcast of the Barclays presentation on Zymeworks’ website. Zymeworks focuses on developing advanced biotherapeutics, including its lead candidate, zanidatamab.
- None.
- None.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that management will participate in five upcoming virtual investor conferences.
- Guggenheim Healthcare Talks Oncology Days, February 11-12, 2021. Zymeworks will be participating in the event; there is no public presentation.
- SVB Leerink’s 10th Annual Global Healthcare Conference, February 22-26, 2021. Zymeworks will be participating in the conference, there is no public presentation.
- Raymond James’ 42nd Annual Institutional Investor Conference, March 1-3, 2021. Zymeworks will be participating in the conference; there is no public presentation.
- Barclays’ Global Healthcare Conference, March 9-11, 2021. Zymeworks is presenting on Thursday, March 11, 2021 at 1:15 p.m. ET.
- Citi's 2021 Winter West Coast Biotech Virtual Bus Tour, March 16-17, 2021. Zymeworks will be participating in the event; there is no public presentation.
Interested parties can access a live webcast of the Barclays presentation via a link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations, which will also host a recorded replay available afterwards.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005760/en/
FAQ
What investor conferences is Zymeworks participating in March 2021?
Is Zymeworks presenting publicly at the Guggenheim Healthcare Talks?
What is Zymeworks' lead clinical candidate?
When will Zymeworks present at the Barclays Global Healthcare Conference?
Where can I watch Zymeworks' Barclays presentation?
